Back to Journals » ImmunoTargets and Therapy » Volume 2
Update on the challenges and recent advances in cancer immunotherapy
Authors Baronzio G, Parmar G, Shubina I, Cassutti V, Giuli S, Ballerini M, Kiselevsky M
Received 16 January 2013
Accepted for publication 19 March 2013
Published 17 June 2013 Volume 2013:2 Pages 39—49
DOI https://doi.org/10.2147/ITT.S30818
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Gianfranco Baronzio,1 Gurdev Parmar,2 Irina ZH Shubina,3 Valter Cassutti,1 Sergio Giuli,1 Marco Ballerini,1 Mikhail Kiselevsky3
1Centro Medico Demetra: Hyperthermia and Immunity Center, Terni, Italy; 2Integrated Health Clinic, Fort Langley, British Columbia, Canada; 3Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
Abstract: This overview provides an analysis of some of the immunotherapies currently in use and under investigation, with a special focus on the tumor microenvironment, which we believe is a major factor responsible for the general failure of immunotherapy to date. It is our expectation that combining immunotherapy with methods of altering the tumor microenvironment and targeting regulatory T cells and myeloid cells will yield favorable results.
Keywords: tumor microenvironment, tumor immunity, immunosuppression, CTLA-4, PD-1, exosomes, myeloid-derived suppressor cells, Tregs
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.